Kornimate/medical-research-clean huggingface dataset:
study of gastrointestinal dysfunction and enteric neural pathology in patients with parkinson's disease

Conditions: Parkinson Disease; Parkinson

Summary: the goal of this research is to determine (1) the feasibility of tethered capsule oct esophageal imaging in the parkinson's disease population; (2) the morphologic changes in the enteric nervous system of the esophagus in patients with parkinson's disease.

the purpose of this study is to establish the esophageal pathology findings as imaged with tethered capsule microscopy in subjects with parkinson disease. images from patients with parkinson disease will be compared to our previously obtained images in healthy subjects to establish the spectrum of esophageal pathologies occurring in patients with parkinson disease by oct imaging. in the case of imaging internal luminal organs, like the esophagus, oct light is delivered via a long catheter. we have developed a new technique termed tethered capsule endomicroscopy (tce). tce involves swallowing a tethered capsule that acquires cross-sectional microscopic images of the entire esophagus as it traverses the luminal organ via peristalsis or is pulled up towards the mouth using tether. the catheter is connected to the imaging system, and the side-viewing optical beam rotates either proximally by a motorized rotary joint or distally by a micro-motor, effectuating circular scanning of the lumen wall. three-dimensional oct of the entire length of the lumen can be acquired by simultaneous rotation and translation of the focused oct beam creating a helical pattern.

Eligibility criteria:
inclusion criteria: * idiopathic parkinson's disease as defined by the united kingdom pd society brain bank criteria * parkinson disease hoehn and yahr stage 2-4 * subjects on stable dose of parkinson disease medications for at least 4 weeks prior to the study screening * subjects between 40 and 85 years old * subjects who are capable of giving informed consent * subjects who had no solid food for at least 4 hours prior to the procedure, and only clear liquids for 2 hours prior to the procedure exclusion criteria: * atypical or secondary parkinson disease * esophageal fistula and/or esophageal strictures with a luminal stricture diameter that is smaller than the diameter of the capsule * recent intestinal resection (within the last six months) * prior gastric, esophageal or oropharyngeal surgery * inability to swallow capsules * pregnancy, according to patient information

Keywords: oct optical coherence tomography tce tethered capsule endomicroscopy
efficacy and safety of sodium benzoate in the management of hyperammonemia in infants, children and adolescent with chronic liver disease.

Conditions: Chronic Liver Disease

Summary: subject will be randomize in two groups. group a will receive drug packets containing 2.5 gm sodium benzoate and 5 gm powdered table sugar for 5days.since the dosage of sodium benzoate is sta t250mg/kg and then 250mg/kg in next 24 hours, each patient would be given 750mg /kg stat and 750mg /kg in next 24 hours,keeping in view that 2/3 of powder used would be powdered sugar in the intervention arm. the dose of the powder used would be doubled in case of the ammonia level more than 300 mcg/dl. the drug will be prepared in sterile water and administered per orally or via the nasogastric tube. all the enrolled patients would be treated with smt as per the recommendations of the easl/aasld 2014 guidelines of management of hepatic encephalopathy. group b will receive 7.5 gm packets of powdered table sugar for 5 days as placebo which is similar in appearance and taste as sodium benzoate.


Eligibility criteria:
inclusion criteria: - infants, children and adolescents under 18 years of age with decompensated chronic liver disease with hyperammonemia \< 400 mcgm and /dl. exclusion criteria: 1. patients who have received sodium benzoate within 1 week priorto evaluation. 2. baseline serum sodium above 155 meq/l 3. patients with grade 3 ascites as per iac classification. 4. patients who did not give a written informed consent.
nonfunctional pancreatic net and pet imaging

Conditions: Diagnosis

Summary: predicting aggressive behavior in the group of nonfunctional pancreatic neuroendocrine tumors (nf p-net) remains a difficult problem in clinical practice. at present, the treatment planning in p-net is significantly restricted by the limited results of conventional imaging. in addition, increasing use of multidetector computed tomography (mdct) and magnetic resonance imaging (mri) is increasing the number of nf p-nets detected. somatostatin receptor scintigraphy (srs) combined with anatomical imaging are the conventional modalities in imaging of p-net, but by these methods the diagnostic accuracy still remains compromised. furthermore, recently encouraging results have been obtained in p-net using 68ga-labelled somatostatin analog, dota-1-nai3-octreotide (68ga-dotanoc) positron emission tomography-computed tomography (pet-ct). the aim of the current project is to evaluate the possibility to enhance the diagnostic accuracy by using dual trace functional imaging 18f-labelled fluorodeoxyglucose (18f-fdg) and 68ga-dotanoc pet-ct imaging in patients with nf p-net. the study consists of 20 patients with nf p-net. the patients enrolled in the study will be imaged 68ga-dotanoc and 18f-fdg pet-ct followed by surgery or follow-up with endoscopic ultrasonography (eus) biopsies. the data will be collected between autumn 2015 and spring 2018.


Eligibility criteria:
inclusion criteria: * suspicion of nonfunctional p-net on primary ct (i.e hypervascularity) or mri * signed informed consent exclusion criteria: * vulnerable study subjects such as described in finnish law concerning clinical studies (disabled, children, pregnant or breast-feeding women, prisoners) will not be included.

Keywords: neuroendocrine tumor pancreas diagnosis positron emission tomography
clinical trial of experienced chinese herbal formulas on different types of precocious puberty

Conditions: Precocious Puberty

Summary: due to various complex factors, the incidence of precocious puberty is increasing rapidly. it severely threatens physical and mental health of children. it's urgent to explore effective ways to control the disease.

in the research, 138 precocious puberty children are randomly divided into the ziyinxiehuo granules group (69 cases) and zishenqinggan granules group(69 cases). patients in ziyinxiehuo granules group are treated with a series of experienced chinese herbal formulas, whereas the zishenqinggan granules group received with different series of experienced chinese herbal formulas.

Eligibility criteria:
1. in the partial precocious puberty children： inclusion criteria: * girls are diagnosed as simple early breast development, and their age of onset is less than 8 years * tanner stages of breast in female patients are tanner ii and tanner iii, diameter of mammary nucleus is less than 3cm； * b-type ultrasonography: the size and volume of uterus and follicle is in the normal range at the same age； * bone age: the bone age in the patients are the same with their actual age. exclusion criteria: * the bone age is advanced by more than 1 standard deviations for chronological age * pseudo sexual precocity, including gonadal tumor,adrenal disease,exogenous intake induced with hormone drugs or food and multiple bone fiber structure dysplasia of precocious puberty (mccune albright syndrome) * heterosexual precocious puberty 2. in the mild true precocious puberty children： inclusion criteria: * girls are diagnosed as idiopathic central precocious puberty，and their age of onset ≤8 years * tanner stages of brest in female patients ≤ tanner iii stage，diameter of mammillary nucleus \< 3cm * b-type ultrasonography: the volume of uterus≥1\~3ml，the diameter of follicle≥4mm;or the length of uterus ≥3.4-4cm * bone age: compared the actual age ,the bone age is no more than 1 year and the bone age \<10 years old; * in master single test: lh \>3 iu/l * gnrh stimulation test: lh/fsh\>0.6, the peak lh 3.5\~5.0 iu/l, the peak lh 3.5\~5.0 iu/l. exclusion criteria: * the central nervous system organic diseases caused sexual precocity * congenital thyroid function reduce disease with precocious puberty, congenital adrenal hyperplasia, adrenal tumor * ovarian or testicular neoplasms, * mccune albright syndrome (precocious puberty with polyostotic fibrous dysplasia and skin pigment abnormalities, pigmentation) * there is a family history of diseases such as tumor, leukemia, diabetes, systemic lupus erythematosus, etc * precocious puberty and partial precocious puberty
a clinical trial to compare the efficacy and safety of 1-week treatment of intravenous n-acetylcysteine (nac) 600 mg twice daily, ambroxol hydrochloride 30 mg twice daily and placebo as expectorant therapies in adult chinese patients with respiratory tract diseases and abnormal mucus secretions

Conditions: Respiratory Tract Diseases; Abnormal Mucus Secretions

Summary: this is a phase 3, multicenter, randomized, rater- and patient-blind, placebo- and active-controlled, 3-arm parallel group clinical trial. patients will be randomized to n-acetylcysteine (nac) or ambroxol or placebo in a 1:1:1 ratio. a total of approximately 333 patients in china will be randomized. the total study duration will be approximately 8 months including the enrolment period of approximately 7 months and the patient participation duration of 1 month or 4 weeks. each patient will undergo a screening period of up to 1 week, a 1-week treatment period and a 2-week follow-up period. this study will be conducted in approximately 15-25 sites in china.


Eligibility criteria:
inclusion criteria: 1. male or female adult (≥18 years old) hospitalized patients with respiratory tract diseases and abnormal mucus secretions such as: acute bronchitis, chronic bronchitis and exacerbations, emphysema, mucoviscidosis and bronchiectasis. 2. chinese ethnicity and/or chinese 3. signed the informed consent form before any study-related procedure 4. sputum viscosity score ≥ 2 at randomization visit 5. expectoration difficulty score ≥ 2 at randomization visit 6. willingness and ability to comply with study procedures exclusion criteria: 1. intolerance or contra-indication to treatment with nac or ambroxol or allergy to any component of the study treatments 2. (for female patients) ongoing pregnancy or lactation, or childbearing potential but unwillingness to adopt abstinence or contraception measures during the study 3. intake of an investigational drug within 1 month before the screening visit 4. use of expectorants or drugs with expectorant effect within 2 days before randomization visit 5. diagnosis of active tuberculosis, lung cancer, pulmonary fibrosis, acute pulmonary thromboembolism or any other respiratory condition that might, in the opinion of the investigator, compromise the safety of the patient or affect the interpretation of the results 6. medical history of and/or illness (including laboratory abnormality) and/or treatment that in the investigator's opinion may interfere with the patient's safety, compliance, or study evaluations 7. serum alanine aminotransferase and/or aspartate transaminase more than 3 times above the upper limit of normal at screening visit 8. serum creatinine more than 3 times above the upper limit of normal at screening visit 9. addiction to alcohol or drugs 10. mental illness, or other reasons for non-cooperation in the investigator's opinion

Keywords: n-acetylcysteine (nac) ambroxol hydrochloride bronchitis cystic fibrosis fibrosis bronchiectasis increased sputum viscosity cough chronic obstructive pulmonary disease (copd)
non-invasive estimation of csf pressure using mri in patients with spontaneous intracranial hypotension

Conditions: Intracranial Hypotension

Summary: the purpose of this study is to estimate the intracranial pressure (icp, the pressure in your head) in subjects with intracranial hypotension (a condition caused by leakage of the fluid that surrounds your brain and spine) using non-invasive magnetic resonance imaging (mri) techniques, and to determine whether changes in estimated icp are seen after treatment of this condition.

subjects with known intracranial hypotension who are scheduled to undergo standard-of-care csf pressure measurement using lumbar puncture prior to planned epidural patch treatment will first undergo a research mri of the brain in order to estimate icp. the imaging protocol is listed in appendix 1. all research scans are performed without intravenous contrast. approximate scan time per session will be 20-22 minutes. subjects will then undergo lumbar puncture according to the standard-of-care treatment plan. estimated values of csf pressure derived from mri will be compared to values measured during lumbar puncture. patients will then undergo standard-of-care epidural patching. a repeat research mri after epidural patching will be performed to assess for differences in pre- and post-treatment scans.

Eligibility criteria:
inclusion criteria: * known diagnosis of intracranial hypotension, established by the following criteria: the presence of orthostatic headache, and one or more of the following criteria: prior csf opening pressure ≤6 cmh20, demonstration of an active spinal csf leak on prior spine imaging, or cranial mri changes of intracranial hypotension.15 * ability to provide informed consent. * expected ability to complete standard-of-care procedures (lumbar puncture and epidural patching) exclusion criteria: * known contraindication to mri (pacemaker, mri incompatible hardware, etc.) * severe claustrophobia or other condition requiring the need for anxiolysis, sedation, or any other medication for mri scanning * inability or expected inability to complete study interventions as scheduled * any known contraindication to standard-of-care procedures (e.g. coagulopathy, allergic reaction to required medication, lack of vascular access, etc.)
development of endoscopic treatment for achalasia

Conditions: Achalasia

Summary: per oral endoscopic myotomy (poem); comparison of two surgical techniques division all the esophageal muscle layers versus division the inner circular muscle layer of the esophagus only.

prior to surgery, all patients undergo upper endoscopy , x-ray "time barium" manometry, 24 hours ph registration. moreover quality of life instrument (rand-36), gsrs (gastrointestinal symptom rating scale) and a dysphagia score (eckardt score) are completed by all patients. follow-up with surveys 3, 6, 12, and 36 months (gsrs, rand-36 and eckardt score). at 3,12 and 36 months an x-ray "time barium" is performed and after 12 months a gastroscopy and at 24 hours esophageal ph monitoring are performed.

Eligibility criteria:
inclusion criteria: * newly diagnosed achalasia * the patient should understand the nature and the purpose of the study and give informed consent exclusion criteria: * previous surgical treatment of achalasia * inability to understand the contents of or follow the protocol * other pathology as an explanation for the obstruction of the esophageal transition
efficacy and safety trial of opc-61815 injection compared with tolvaptan 15-mg tablet in patients with congestive heart failure

Conditions: Congestive Heart Failure

Summary: to confirm the non-inferiority of opc-61815 16-mg injection to tolvaptan 15-mg tablet using as the primary endpoint the change in body weight following 5-day intravenous administration of opc-61815 16-mg injection or 5-day oral administration of tolvaptan 15-mg tablet to chf patients with volume overload despite having received diuretics other than vasopressin antagonists


Eligibility criteria:
inclusion criteria: * patients who are currently on treatment with any of the following diuretics 1. loop diuretics equivalent to furosemide tablet or fine granules at a dose of 40 mg/day or higher 2. concomitant use of a loop diuretic and a thiazide diuretic (including thiazide analogs) at any dose 3. concomitant use of a loop diuretic and an aldosterone antagonist or potassium-sparing diuretic agent at any dose * patients with congestive heart failure in whom lower limb edema, pulmonary congestion, and/or jugular venous distension due to volume overload is present * patients who are currently hospitalized or who are able to be hospitalized during the trial exclusion criteria: * patients with acute heart failure * patients who are on a ventricular assist device * patients who are unable to sense thirst or who have difficulty with fluid intake
effectiveness of echogenic and nonechogenic needles in ultrasound guided infraclavicular brachial plexus block

Conditions: Upper Extremity Injury Trauma

Summary: in this prospective, randomized, double blinded study, the needle tip and needle shaft visibility of echogenic and nonechogenic needle were compared in ultrasound guided infraclavicular brachial plexus block. sixty patients scheduled for upper extremity surgery were included in the study. patients were randomised into two groups, group e (echogenic) and group ne (nonechogenic) with 30 subjects in each group. under ultrasound guidance infraclavicular brachial plexus block was performed. in group e, pajunk sonoplex echogenic needle was used and in group ne, stimuplex braun nonechogenic needle was used. the subjective assessment for needle tip/shaft visibility as scored by the performer and the objective assessment from the recorded block procedure video were noted.

the aim of the investigators study was to find out the better among the echogenic and nonechogenic needle in needle tip/shaft visibility and the block success rate in ultrasound guided infraclavicular brachial plexus block. sixty patients were randomized into two groups, group e (echogenic group) and group ne (nonechogenic group) with thirty patients in each group. the ultrasound imaging of each nerve block was video recorded for later analysis. recording commenced from skin puncture and stopped at the time of final needle removal (total block time). after each block the performer was asked to subjectively score the percentage time he had visualized the needle tip and needle shaft on a 5 point scale (1 = 0%-20%, 2 = 20%-40%, 3 = 40%- 60%, 4 = 60%-80%, 5 = 80%-100%). the recorded video was later analysed by an investigator. an objective measurement of percentage needle tip visibility and needle shaft visibility was calculated for each nerve block using the formula, time in view (needle tip) / total block time x 100 time in view (needle shaft) / total block time x 100 the subjective assessment for needle tip/shaft visibility as scored by the performer and the objective assessment from the recorded block procedure video were noted. other block parameters were also compared.

Eligibility criteria:
inclusion criteria: * 18-60 years, both male and female scheduled for upper extremity surgery exclusion criteria: * clinically significant coagulopathy * local anesthetic allergy * preexisting motor or sensory deficit in the operative limb * uncontrolled hypertension and unstable ischemic heart disease * body mass index \> 35 * patients who needs general anaesthesia for surgery
effects of spinal stabilization exercises focusing on the pelvic floor in women with overactive bladder

Conditions: Overactive Bladder

Summary: the aim of this study is to examine the effects of spinal stabilization exercises focusing on the pelvic floor on urinary symptoms, spinal stability, pelvic floor muscle functions, quality of life and perception of recovery in women with overactive bladder.

overactive bladder (oab) is defined by the international continence society and the international society of urogynecology as urinary urgency with or without urinary incontinence, usually accompanied by frequency and nocturia. among the treatment options of oab; first-line treatments include lifestyle recommendations, exercise approaches, and bladder training. lifestyle recommendations; healthy lifestyle includes behavioral changes. spinal stabilization exercise also aims to improve the neuromuscular control, strength and endurance of the muscles that are important in maintaining trunk stability. in recent years, it has been stated that trunk stability is impaired in women with oab. however, no study was found on spinal stabilization exercises in patients with oab.

Eligibility criteria:
inclusion criteria: * being between the ages of 18-65 * women with a diagnosis of overactive bladder * women who volunteered to participate in the study exclusion criteria: * women with only stress urinary incontinence * presence of advanced pelvic organ prolapse * having a mental problem that will prevent cooperation in assessment and/or practices * women with the presence of a malignant condition * concomitant neurological disease and/or neurogenic bladder * presence of infection * pregnancy
plaque reduction sesame oil

Conditions: Dental Plaque; Gingivitis; Oral Microbial Colonization

Summary: the goal of this clinical trials to learn about potential additives in reducing dental plaque. the main questions it aims to answer is: • is there a difference in the plaque reducing effect of oil pulling with sesame oil compared to rinsing with distilled water? participants will rinse with 15 ml of their allocated liquid for 15 min every morning for 8 weeks. researchers will compare sesame oil against distilled water to see if there is a difference in the plaque reducing effect.


Eligibility criteria:
inclusion criteria: * age ≥ 18 years * contractual capability * the presence of ≥ 10 teeth, * community periodontal index of treatment needs (cpitn) grade 1 or 2 exclusion criteria: * missing consent * community periodontal index of treatment needs (cpitn) grade 0, 3 or 4 * pregnancy or breastfeeding * systemic diseases or conditions that are associated with an increased risk of infection or necessitate concomitant antibiotic therapy with dental treatment * mental and behavioral disorders that impede (verbal) communication * allergy against sesame(oil) * intake of antibiotics 6 months prior to or during study duration * intake of medication potentially influencing gingival inflammation or bleeding (e.g. anticoagulants, cortisone) * infectious diseases (e.g. hiv, hepatitis b or c) * fixed orthodontic appliances * ongoing oil pulling or mouth rinsing * adult guardianship * insufficient nasal breathing